Drugs /
tiragolumab
Overview
Clinical Trials
Tiragolumab has been investigated in 17 clinical trials, of which 17 are open and 0 are closed. Of the trials investigating tiragolumab, 3 are phase 1 (3 open), 4 are phase 1/phase 2 (4 open), 6 are phase 2 (6 open), and 4 are phase 3 (4 open).
PD-L1 Expression, PD-L1 High Expression, and PD-L1 Low Expression are the most frequent biomarker inclusion criteria for tiragolumab clinical trials.
Esophageal squamous cell carcinoma, head and neck squamous cell carcinoma, and non-small cell lung carcinoma are the most common diseases being investigated in tiragolumab clinical trials [2].
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].
2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.